Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miki Horiguchi

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
The Oncologist|September 12, 2018
How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?Miki Horiguchi, Michael J Hassett, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2017
Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial CancerMiki Horiguchi, Hajime Uno, Lee-Jen Wei
Statistics in Medicine|June 15, 2026
Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for ImplementationMiki Horiguchi, Lu Tian, Satoshi Hattori, et al.
Statistics in Medicine|April 11, 2025
A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-To-Event Outcomes Using Average Hazard With Survival WeightZihan Qian, Lu Tian, Miki Horiguchi, et al.
Pharmaceutical Statistics|August 8, 2025
Comment on "Average Hazard as Harmonic Mean" by Chiba (2025)Hajime Uno, Lu Tian, Miki Horiguchi, et al.
Statistics in Medicine|April 24, 2018
A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trialsMiki Horiguchi, Angel M Cronin, Masahiro Takeuchi, et al.
Lifetime Data Analysis|October 14, 2025
Assessing delayed treatment benefits of immunotherapy using long-term average hazard: a novel test/estimation approachMiki Horiguchi, Lu Tian, Kenneth L Kehl, et al.
Biometrics|May 21, 2024
Regression models for average hazardHajime Uno, Lu Tian, Miki Horiguchi, et al.
AIDS (London, England)|July 28, 2023
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapyDebjani Guha, Vikas Misra, Jun Yin, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2023
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapyDebjani Guha, Vikas Misra, Jun Yin, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
The Oncologist|September 12, 2018
How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?Miki Horiguchi, Michael J Hassett, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2017
Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial CancerMiki Horiguchi, Hajime Uno, Lee-Jen Wei
Statistics in Medicine|June 15, 2026
Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for ImplementationMiki Horiguchi, Lu Tian, Satoshi Hattori, et al.
Statistics in Medicine|April 11, 2025
A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-To-Event Outcomes Using Average Hazard With Survival WeightZihan Qian, Lu Tian, Miki Horiguchi, et al.
Pharmaceutical Statistics|August 8, 2025
Comment on "Average Hazard as Harmonic Mean" by Chiba (2025)Hajime Uno, Lu Tian, Miki Horiguchi, et al.
Statistics in Medicine|April 24, 2018
A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trialsMiki Horiguchi, Angel M Cronin, Masahiro Takeuchi, et al.
Lifetime Data Analysis|October 14, 2025
Assessing delayed treatment benefits of immunotherapy using long-term average hazard: a novel test/estimation approachMiki Horiguchi, Lu Tian, Kenneth L Kehl, et al.
Biometrics|May 21, 2024
Regression models for average hazardHajime Uno, Lu Tian, Miki Horiguchi, et al.
AIDS (London, England)|July 28, 2023
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapyDebjani Guha, Vikas Misra, Jun Yin, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2023
Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapyDebjani Guha, Vikas Misra, Jun Yin, et al.
Pageof 4